newsfilter
← Latest News
GlobeNewswire·

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel